卵巢癌每年檢測并沒有降低死亡率

A large-scale randomised trial of annual screening for ovarian cancer, funded by the NIHR, did not succeed in reducing deaths from the disease, despite one of the screening methods tested detecting cancers earlier.

一項由NIHR資助的卵巢癌年度篩查的大規(guī)模隨機試驗表明，盡管某種篩查方法更早地檢測出癌癥，但未能成功地降低該病的死亡率。

Results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) have been published in a report in the medical journal The Lancet.

英國卵巢癌篩查協(xié)作試驗(UKCTOCS)的結(jié)果發(fā)表在醫(yī)學(xué)雜志《柳葉刀》上。

In the UK, 4,000 women die from ovarian cancer each year. It is not usually diagnosed until it is at a late stage and hard to treat. UKCTOCS was designed to test the hypothesis that a reliable screening method that picks up ovarian cancer earlier, when treatments are more likely to be effective, could save lives.

在英國，每年有4000名婦女死于卵巢癌。病患沒有前期篩查，發(fā)現(xiàn)時已經(jīng)是晚期，難以治療。UKCTOCS的設(shè)計是為了驗證這樣一個假設(shè)，即在治療尚且有效時更早地發(fā)現(xiàn)卵巢癌，從而挽救生命。

The latest analysis looked at data from more than 200,000 women aged 50-74 at recruitment who were followed up for an average of 16 years. The women were randomly allocated to one of three groups: no screening, annual screening using an ultrasound scan, and annual multimodal screening involving a blood test followed by an ultrasound scan as a second line test.

這項最新的分析調(diào)查了20多萬名年齡在50-74歲之間的女性的數(shù)據(jù)，這些女性平均隨訪了16年。這些婦女被隨機分配為三組：不篩查，每年進行篩查，每年進行多模式篩查，包括血液檢測，然后進行超聲掃描作為二線檢測。

The researchers found that, while the approach using multimodal testing succeeded in picking up cancers at an early stage, neither screening method led to a reduction in deaths.

研究人員發(fā)現(xiàn)，雖然使用多模式檢測的方法成功地在早期發(fā)現(xiàn)了癌癥，但這兩種篩查方法都沒有降低死亡率。

Professor Usha Menon (MRC Clinical Trials Unit at UCL), lead investigator of UKTOCS, said: “UKCTOCS is the first trial to show that screening can definitely detect ovarian cancer earlier. However, this very large, rigorous trial shows clearly that screening using either of the approaches we tested did not save lives. We therefore cannot recommend ovarian cancer screening for the general population using these methods.

UKCTOCS的首席研究員Usha Menon教授(UCL的MRC臨床試驗部門)說：“UKCTOCS是第一個表明篩查可以更早發(fā)現(xiàn)卵巢癌的試驗。然而，這個非常大的、嚴格的試驗清楚地表明，使用我們測試的任何一種方法進行篩查都不能挽救生命。因此，我們不能推薦使用這些方法對普通人群進行卵巢癌篩查。”

“We are disappointed as this is not the outcome we and everyone involved in the trial had hoped and worked for over so many years. To save lives, we will require a better screening test that detects ovarian cancer earlier and in more women than the multimodal screening strategy we used.”

“我們很失望，因為這不是我們多年來所希望和努力的結(jié)果。為了挽救生命，我們需要一種更好的篩查方法，比我們使用的多模式篩查策略更早地發(fā)現(xiàn)卵巢癌，并應(yīng)用到更多的女性中。”

Professor Nick Lemoine, Medical Director, NIHR Clinical Research Network, said: “These important findings from a large-scale trial, involving 200,000 participants, show that annual screening did not succeed in reducing deaths from ovarian cancer.

NIHR臨床研究網(wǎng)絡(luò)的醫(yī)學(xué)主任Nick Lemoine教授說：“一項涉及20萬參與者的大規(guī)模試驗的這些重要發(fā)現(xiàn)表明，每年一次的篩查并沒有成功地減少卵巢癌的死亡率。

“However, it’s important to note that negative results can be as important as positive. The study has provided important new evidence and insights into how to conduct and analyse future large-scale randomised clinical trials into ovarian cancer, in the hope that this will prevent and diagnose this disease more effectively in the future.

“然而，值得注意的是，負面結(jié)果可能和正面結(jié)果一樣重要。這項研究為今后如何開展和分析卵巢癌的大規(guī)模隨機臨床試驗提供了重要的新證據(jù)和見解，希望能在今后更有效地預(yù)防和診斷卵巢癌。

"We thank every single person who took part.”

“我們感謝每一位參與者。”